FDC.BO
FDC.BO
INE258B01022
FDC LTD.
Loading chart...

Company Profile

FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastroenterology, ophthalmology, anti-diabetics, cardiovascular care, respiratory care, gynaecology, dermatology, paediatrics, analgesics, vitamins, and nutritional health in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutions. It also provides functional food, such as flavoured oral rehydration solution powders, ready-to-drink electrolyte beverages, vitamin-enriched supplements, antioxidant blends and protein-fortified drinks; and various active pharmaceutical ingredients. The company sells its products under the Zifi, Zifi-0, Zocon, Mycoderm, Zathrin, Victofol, Cotaryl, Ziglim-M, Amodep-AT, MumMum 1, Victofol Injection, Simyl MCT, Victofol – C, Electral, and Enerzal brands. It also exports its products to approximately 50 countries. FDC Limited was founded in 1936 and is based in Mumbai, India.

Related stocks

AARTIPHARM.NS
AARTIPHARM.NS • India
AARTI PHARMALABS LIMITED
855.5 INR
801.58M USD 1Y +2.5%
PGHL.BO
PGHL.BO • India
PROCTER & GAMBLE HEALTH LIMITE
5,215.55 INR
894.55M USD 1Y -17.2%
IOLCP.BO
IOLCP.BO • India
IOL CHEMICALS & PHARMACEUTICAL
200.85 INR
609.17M USD 1Y +100.2%
SPARC.NS
SPARC.NS • India
SUN PHARMA ADV.RES.CO.LTD
185.6 INR
622.35M USD 1Y +46.6%
STAR.NS
STAR.NS • India
STRIDES PHARMA SCI LTD
1,085.3 INR
1.03B USD 1Y +37.4%
ASTRAZEN.BO
ASTRAZEN.BO • India
ASTRAZENECA PHARMA INDIA LTD.
5,831.85 INR
1.51B USD 1Y -38.5%
NATCOPHARM.NS
NATCOPHARM.NS • India
NATCO PHARMA LTD.
789.4 INR
1.5B USD 1Y -1.7%
300485.SZ
300485.SZ • China
SCIENCE SUN
8.57 CNY
617.67M USD 1Y -24%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
29.4% p.a.
Max Drawdown (5Y)
-47.5%
Sharpe Ratio (5Y)
-0.14
Beta Factor
0.20
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (29.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -50.6% in the extended horizon.
ende